The efficacy and safety of abiraterone acetate in patients with high-risk prostate cancer: a meta-analysis based on six randomized control trials

Guobin Tan; Zijun Xuan; Zhiqin Li; Shuitong Huang; Guangming Chen; Yonglu Wu; Xianxi Chen; Zhijin Liang; Aiming Wu

doi:10.21037/tau-20-1058

The efficacy and safety of abiraterone acetate in patients with high-risk prostate cancer: a meta-analysis based on six randomized control trials

Transl Androl Urol. 2020 Aug;9(4):1691-1699. doi: 10.21037/tau-20-1058.

Authors

Guobin Tan¹, Zijun Xuan², Zhiqin Li¹, Shuitong Huang¹, Guangming Chen¹, Yonglu Wu¹, Xianxi Chen¹, Zhijin Liang¹, Aiming Wu¹

Affiliations

¹ Department of Urology, Maoming People's Hospital, Maoming, China.
² Department of Urology, Dongguan Kanghua Hospital, Dongguan, China.

Abstract

Background: Abiraterone acetate, a CYP17 enzyme inhibitor, can block the synthesis of androgens in the adrenal gland, prostate, and testis. The purpose of this study was to investigate the efficacy and safety of abiraterone acetate in high-risk prostate cancer patients, including metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).

Methods: A meta-analysis based on 6 randomized controlled trials (RCTs) was undertaken in compliance with the guidelines of systematic reviews and meta-analyses. Databases including PubMed, EMBASE, and Cochrane library were searched for relevant literature through to September 2019.

Results: The pooled analysis reported abiraterone acetate showed significant efficacy in high-risk prostate cancer patients, including overall survival (OS) [HR 0.66, 95% confidence interval (CI), 0.61-0.73, P<0.001], the time to prostate-specific antigen (PSA) progression (HR 0.45, 95% CI, 0.34-0.59, P<0.001), progression-free survival (PFS) (according to radiographic evidence) (HR 0.55, 95% CI, 0.45-0.68, P<0.001) and PSA response rate (RR 2.49, 95% CI, 1.47-4.22, P<0.001). A subgroup analysis was carried out due to the significant heterogeneity between the studies. The incidence of arthralgia (RR 1.19), hypokalemia (RR 2.47), cardiac disorder (RR 1.48), and hypertension (RR 1.57) in the abiraterone acetate group was moderately higher than the control group.

Conclusions: The efficacy and safety of abiraterone acetate as an androgen receptor (AR) pathway targeted drug in high-risk prostate cancer patients was confirmed.

Keywords: Abiraterone acetate; efficacy; prostate cancer; safety.